Evidence map›Paper›PMID 42184020›Full record

ReviewClinical and experimental medicine2026

A review of deep learning-based multimodal data integration of lung cancer.

Ya Qin, Simin Wang, Dan Wu, Yanhua Fei, Weiping Ding, Qiong Wang, Runwei Guan, Xiao Liang

Abstract readReview
In one paragraph

Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ya QinDepartment of Oncology, The Affiliated Jiangyin Hospital of Nantong University, 163# Shoushan Road, Jiangyin, 214400, Jiangsu, People's Republic of China.
Simin WangDepartment of Oncology, The Affiliated Jiangyin Hospital of Nantong University, 163# Shoushan Road, Jiangyin, 214400, Jiangsu, People's Republic of China.
Dan WuDepartment of Oncology, The Affiliated Jiangyin Hospital of Nantong University, 163# Shoushan Road, Jiangyin, 214400, Jiangsu, People's Republic of China.
Yanhua FeiDepartment of Oncology, The Affiliated Jiangyin Hospital of Nantong University, 163# Shoushan Road, Jiangyin, 214400, Jiangsu, People's Republic of China.
Weiping DingSchool of Artificial Intelligence and Computer Science, Nantong University, Nantong, 226019, People's Republic of China.
Qiong WangDepartment of Oncology, The Affiliated Jiangyin Hospital of Nantong University, 163# Shoushan Road, Jiangyin, 214400, Jiangsu, People's Republic of China. wangqiong55@hotmail.com.
Runwei GuanThrust of Artificial Intelligence, The Hong Kong University of Science and Technology (Guangzhou), Guangzhou, 511453, People's Republic of China. runwayrwguan@hkust-gz.edu.cn.
Xiao LiangDepartment of Oncology, The Affiliated Jiangyin Hospital of Nantong University, 163# Shoushan Road, Jiangyin, 214400, Jiangsu, People's Republic of China. heroshaw@hotmail.com.

Funding

National Natural Science Foundation of China 82503895Natural Science Foundation of Jiangsu Province BK20250318Wuxi Administration of Traditional Chinese Medicine Project ZYYB34Youth Project of Jiangyin Municipal Health Commission Q202305
6 · The paper itself

Abstract

This is a narrative review that provides a perspective on the recent advances in deep learning (DL)-driven multimodal data integration for lung cancer. Lung cancer remains the most prevalent malignancy and the leading cause of cancer-related mortality worldwide. Despite growing awareness and therapeutic innovations, the majority of cases are diagnosed at advanced stages, resulting in persistently poor survival rates. In recent years, artificial intelligence (AI) has demonstrated transformative potential in oncology research, particularly through the integration of heterogeneous biomedical data modalities. The fusion of radiological imaging, histopathological slides, genomic and transcriptomic profiles, and electronic health records has consistently outperformed unimodal approaches by capturing complementary biological and clinical information. DL-based multimodal integration frameworks have shown promise in improving diagnostic accuracy, stratifying patients according to therapeutic response, and predicting long-term prognosis, thereby contributing to precision oncology. By leveraging the synergistic strengths of diverse data sources, multimodal AI models can enable more accurate and individualized strategies for diagnosis, treatment planning, and longitudinal disease monitoring, ultimately improving clinical outcomes for patients with lung cancer.

Indexed as

Deep LearningLung NeoplasmsArtificial IntelligenceElectronic Health RecordsHumansPrognosisArtificial intelligenceDeep learningLung cancerMultimodal data integration

Identifiers

PMID42184020
PMCPMC13385053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.